10X Genomics Inc (TXG)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $7.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
10X Genomics Inc (TXG) Stock Forecast
Analysts expect 10X Genomics (TXG) to earn $0.06 per share in the fiscal year ending Dec 31, 2026, on revenue of $631.04M. Of 17 analysts, 6 rate the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.09.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.59, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 35% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 5.9% |
| Buy | 5 | 29.4% |
| Hold | 11 | 64.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 50.0% and revenue estimates rise 11.7%.
- Fiscal year ending Dec 31, 2026
- $0.06
- EPS consensus, revenue $631.04M
- Fiscal year ending Dec 31, 2027
- $0.09
- EPS consensus, revenue $705.00M
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.06 | -$0.10 to $0.18 | 3 | $631.04M | $627.30M to $635.01M | 14 |
| Dec 31, 2027 | $0.09 | $0.01 to $0.20 | 3 | $705.00M | $663.09M to $746.50M | 15 |
Quarterly Estimates
The EPS consensus rises from -$0.22 for the quarter ending Dec 31, 2026 to -$0.03 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.22 | -$0.33 to -$0.07 | 16 | $179.68M | $163.56M to $190.99M | 17 |
| Mar 31, 2027 | -$0.03 | -$0.03 to -$0.03 | 1 | $167.33M | $156.88M to $180.00M | 10 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 40.0% from $0.10.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.06 | $0.04 | $0.04 | $0.11 | $0.10 | -36.7% |
| Fiscal year ending Dec 31, 2027 | $0.09 | $0.08 | $0.08 | $0.20 | $0.20 | -57.4% |
| Quarter ending Mar 31, 2027 | -$0.03 | -$0.03 | $0.02 | $0.02 | $0.01 | N/A |
Frequently Asked Questions About TXG
What is the TXG stock forecast?
Consensus analyst estimates put 10X Genomics's EPS at $0.06 for the fiscal year ending Dec 31, 2026, on revenue of $631.04M. The consensus rating from 17 analysts is Hold.
How do analysts rate TXG stock?
Of 17 analysts covering 10X Genomics, 1 rates it Strong Buy, 5 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from TXG next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.06, with estimates from -$0.10 to $0.18 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.09, with estimates from $0.01 to $0.20 from 3 analysts.
What revenue do analysts expect from 10X Genomics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $631.04M, with estimates from $627.30M to $635.01M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $705.00M, with estimates from $663.09M to $746.50M.
How many analysts cover TXG?
17 analysts rate 10X Genomics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts